Insights

Acquisition Implication There is a recent acquisition by Harmony Biosciences for Epygenix, signaling a potential exit or partnership interest from buyers in the rare epilepsy space. This creates a market signal for sales teams to target late-stage CNS opportunities and explore licensing or collaboration options with acquirers seeking complementary assets.

Rare Epilepsy Franchise Epygenix focuses on Dravet syndrome and other genetic epilepsies, positioning it within a high-need, high-value segment. There may be opportunities to offer companion diagnostics, specialized patient registries, or platform-based collaborations with companies serving similar indications.

Phase 3 Pipeline With near-term Phase 3 activity in Lennox-Gastaut syndrome cited in news, there could be cross-sell opportunities for CNS supportive therapies, antiseizure drug adjunctions, or services around trial site networks and enrollment services to accelerate concurrent or follow-on studies.

Financial and Resources Signals Revenue under $1M and a small team suggest a potential need for strategic partnerships, co-development deals, or outsourced CRO/clinical operations to scale development activities without heavy internal headcount increases.

Leadership and Governance Past leadership hires in 2022 for CEO and CFO indicate a phase of governance maturation. This may present outreach angles for advisory, board-level partnerships, or strategic fundraising conversations aligned with late-stage CNS assets and potential acquirer interest.

Similar companies to Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc. Tech Stack

Epygenix Therapeutics, Inc. uses 8 technology products and services including WordPress, Google Fonts API, Twemoji, and more. Explore Epygenix Therapeutics, Inc.'s tech stack below.

  • Content Management System
  • Google Fonts API
    Font Scripts
  • Twemoji
    Font Scripts
  • jQuery
    Javascript Libraries
  • PHP
    Programming Languages
  • Yoast SEO
    Search Engines
  • MediaElement.js
    Video Players
  • Google Analytics
    Web Analytics

Media & News

Epygenix Therapeutics, Inc.'s Email Address Formats

Epygenix Therapeutics, Inc. uses at least 2 email formats:
Epygenix Therapeutics, Inc. Email FormatsExamplePercentage
FirstLast@epygenix.comJohnDoe@epygenix.com
75%
FLast@epygenix.comJDoe@epygenix.com
25%

Frequently Asked Questions

What is Epygenix Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Epygenix Therapeutics, Inc.'s official website is epygenix.com and has social profiles on LinkedIn.

How much revenue does Epygenix Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of July 2026, Epygenix Therapeutics, Inc.'s annual revenue is estimated to be <$1M.

What is Epygenix Therapeutics, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Epygenix Therapeutics, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Epygenix Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of July 2026, Epygenix Therapeutics, Inc. has approximately 3 employees across 1 continents, including North America. Key team members include Chief Executive Officer: A. Y., President And Chief Executive Officer And Board Member: D. C. and President And Chief Executive Officer: L. H. Explore Epygenix Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Epygenix Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Epygenix Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Epygenix Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Epygenix Therapeutics, Inc.'s tech stack includes WordPress, Google Fonts API, Twemoji, jQuery, PHP, Yoast SEO, MediaElement.js and Google Analytics.

What is Epygenix Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Epygenix Therapeutics, Inc.'s email format typically follows the pattern of FirstLast@epygenix.com. Find more Epygenix Therapeutics, Inc. email formats with LeadIQ.

When was Epygenix Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Epygenix Therapeutics, Inc. was founded in 2016.
Epygenix Therapeutics, Inc. logo

Epygenix Therapeutics, Inc.

Biotechnology ResearchNew Jersey, United States2-10 Employees

In 2024, Epygenix emerged in the news regarding the initiation of a second phase 3 study in children with Lennox-Gastaut syndrome, highlighting ongoing late-stage development within its epilepsy program. The firm has been positioned within the broader CNS and rare epilepsy landscape, seeking to expand its pipeline through rigorous clinical evaluation. This context places Epygenix within the specialty biopharma segment dedicated to high-need neurological conditions, operating under a focused, research-driven mandate.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
2-10

Section iconFunding & Financials

  • <$1M

    Epygenix Therapeutics, Inc.'s revenue is estimated to be in the range of <$1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.